Although endocrine therapy using tamoxifen or aromatase blockers is a firm part of hormone receptor–positive breast cancer, no randomized studies could be found addressing the effect of these adjuvant therapies for the situation of advanced breast cancer with brain metastases. The gene discussed is CYP19A1; the disease is breast cancer.